What neuroscience investors actually fund
"Neuroscience" covers three very different businesses, and each one has its own kind of investor. Before you build a list, work out which one you are.
- Therapeutics. Drugs for conditions like Alzheimer's, Parkinson's, epilepsy, depression and ALS. These are backed by biotech investors who are used to long trials and all-or-nothing results.
- Neurotech devices. Neuromodulation, implants, brain-computer interfaces and surgical tools. The backers here overlap with medical device investors, and they'll ask about your FDA pathway early.
- Digital brain health. Software for diagnosis, monitoring, cognitive care and mental health. This sits closer to digital health investing, where you're judged on users, outcomes and who pays.
The 800+ investors tagged to neuroscience in Angel Match span all three. That's why two investors on the same list can want completely different things from you. A drug investor wants to see your preclinical data and your Phase I plan. A digital health investor wants to see retention and a paying customer. Send the same deck to both and one of them will pass in the first minute.
There's one more thing the data shows. Almost every investor on the first page of this list also carries the health care tag, and most have dozens of other markets on their profile. So a lot of "neuroscience investors" are really broad health care investors who've done a brain deal or two. True neuro specialists are a smaller group inside the list. Check each investor's past deals before you write to them, and put the specialists at the top.
Where neuroscience investors are based
About three in five neuroscience investors in Angel Match are based in the United States. Within the US, three states do most of the work. California leads by a wide margin and holds about a third of the US total. New York and Massachusetts come next, and the three together account for nearly two thirds of US-based neuroscience investors.
The city data tells you something the state data hides. San Francisco is the top city and New York City is second. But Boston and Cambridge both make the top ten on their own, which is what you'd expect from a region packed with hospitals, universities and drug companies. If you're building a therapeutic, the Boston area deserves extra attention even though its count is smaller.
Two names on the city list are worth a second look. Minneapolis makes the top ten, ahead of plenty of bigger cities. Minnesota has a long history in medical devices, so if you're building neuromodulation or implant hardware, investors there already speak your language. Melbourne also makes the list and ranks above Los Angeles. If you're an Australian neuro founder, you don't have to start your raise overseas.
Outside the US, Europe is the next biggest pool, with at least a fifth of the list. The United Kingdom and France lead, followed by Switzerland, Germany and the Netherlands. Paris and London are close to level as cities, so French founders aren't at a disadvantage here.
Stages and investor types
Seed is the most common stage on this list by a long way. About a third of neuroscience investors are tagged to seed rounds, and early stage venture is second with about a fifth. Pre-seed is a much smaller group, and only a few dozen investors are tagged to each of Series A and Series B.
That shape matters for how you plan. In neuroscience, the earliest money often doesn't come from investors at all. It comes from research grants, university programs and disease foundations. The stage data backs that up, with far more investors here tagged to seed than to pre-seed. So treat pre-seed as the stage where you collect proof, and seed as the stage where you pitch it.
On investor type, about three in five are venture capitalists and a little under half are angels. Many profiles carry both tags. Angel checks usually run $25,000 to $500,000, and venture checks run from $2 million to $100 million or more. Trials and device builds are expensive, so angels alone rarely get you all the way. They're best used to fund one clear experiment that makes the venture round possible.
One group is small but matters more than its size: corporate venture investors. Drug and device companies are the most likely buyers of a neuro startup, and their venture arms invest early to get a close look. Jason Hafler of Sanofi Ventures is one example on this list. A corporate investor on your cap table can open doors, but ask how it affects your options if a rival company wants to buy you later.
Why neuroscience is a harder pitch than most of health care
Investors know the odds in this field, and you should too. A study by BIO, Informa and QLS Advisors tracked drug programs from 2011 to 2020. Only 5.9% of neurology programs that entered Phase I went on to win FDA approval. The average across all disease areas was 7.9%.
The same study found that neurology drugs that did get approved took a little over 11 years from Phase I, longer than the 10.5-year average. It also found that neurology's risk tends to show up late. Programs get through Phase II at close to the normal rate and then stumble in Phase III, after the most expensive trials are already paid for.
So every neuroscience investor is asking the same question: why will this one work when so many haven't? Your pitch has to answer it before they ask. The strongest answers are concrete. You have a biomarker that picks the right patients. You have an endpoint regulators already accept. You have early human data, not just animal data. Across all disease areas in that study, programs that chose patients using biomarkers were about twice as likely to reach approval.
Long timelines also change your cash math. A software startup can raise 18 months of money and expect to hit real milestones. A neuro startup might spend that long on a single study. Before you raise, work out your runway against the milestone that moves your valuation, not against the calendar.
Where neuroscience money is going in 2026
The headlines say neurotech funding is booming. That's true, but it's lopsided. Neurotech Reports looked at neurotechnology deals in August 2026 and found that brain-computer interface companies took 76% of the deal capital but made up only 36% of the deals. Even inside that group the money was bunched up. Brain-computer interface rounds under $50 million added up to just over 10% of the capital those companies raised.
Here's what that means for you. If you're not building a brain implant, don't benchmark your raise against those rounds. And even if you are, most of that money went to a handful of names. Smaller device companies are raising in a much tighter market. The same report says the grant funding that used to carry device startups to their first human studies has become harder to predict.
The better news is at the other end. Big drug companies are still willing to pay for neuroscience. In April 2025, Johnson & Johnson closed its purchase of Intra-Cellular Therapies in a deal worth more than $14 billion. Exits like that are why investors keep funding a field with tough odds. It also tells you what belongs in your deck: who would buy you, and what you'd need to show them first.
How to pitch a neuroscience investor
Neuroscience investors read a lot of science and fund very little of it. A few things get you past the first read.
- Lead with the patient and the endpoint. Say which condition you treat, which patients and how you'll measure success. "A platform for brain disorders" reads as no plan at all.
- Show your regulatory path. For a device, name the FDA route you expect, whether that's 510(k), De Novo or PMA. For a drug, say how far you are from an IND. Investors price your company off this, so don't make them guess.
- Explain who pays. A cleared device with no reimbursement is a hard business. If you have a billing code, a payer pilot or a hospital budget line in sight, say so.
- Put your clinical people up front. A neurologist, psychiatrist or neurosurgeon who'll put their name on your work counts for a lot in this field.
- Tie the ask to one milestone. Pick the result that changes your risk, like first-in-human data or FDA clearance, and work out how much you need to raise to reach it with room to spare.
Keep the first email short. Two or three lines on the condition, the data you have and the milestone this round buys. Save the mechanism of action for the call.
Narrowing down your neuroscience investor list
With 800+ neuroscience investors on this list, your first job is to cut it down. Sort by whether they back drugs, devices or digital health, then by stage, then by who's done a real brain deal before. A list of 30 well-matched names beats a blast to all of them, and when you're ready you can send and track those first emails from one place.
Health care investors
